Boston Scientific to Acquire BridgePoint Medical

September 19, 2012—Boston Scientific Corporation (Natick, MA) announced that it has signed a definitive agreement to acquire BridgePoint Medical, Inc. (Minneapolis, MN), developer of a catheter-based system to treat coronary chronic total occlusions (CTOs). The transaction is expected to close in the fourth quarter of 2012, subject to customary closing conditions.

According to the announcement, the BridgePoint Medical CTO system is composed of the CrossBoss CTO crossing catheter and the Stingray CTO re-entry system. It is designed to navigate highly occluded coronary arteries to restore blood flow. The system has received both US Food and Drug Administration clearance and CE Mark approval.